Companies: 10,795·Total market cap: $144.5T
BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOTNASDAQHealthcare● Active
$8.00
+$0.22(+2.83%)
Market Cap$640856832
P/E Ratio
52W High$14.87
52W Low$7.6

BridgeBio Oncology Therapeutics Inc. (BBOT) Shares Outstanding — Overview

Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.

BBOT · shares outstanding · updated Jun 9, 2026

Key metrics

Basic Shares Outstanding · Weighted average · fiscal year
31.1M +87.21% YoY Change
FY · as of Dec 31, 2025 · Reported in USD
vs 16.6M in FY 2024
Diluted Shares Outstanding
31.1M
incl. options, RSUs, convertibles
Dilution Spread
+0.00%
Diluted vs Basic
YoY Change
+87.21%
year-over-year
Source: FMP /income-statement · /shares-float · SEC 10-K / 10-QUpdated: 2026-06-09

Shares Outstanding Growth Rate

3-Year CAGRincreasing
+15.0%
2022 → 2025
5-Year CAGR
10-Year CAGR

Negative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials

Shares outstanding history

↓ Decrease — typically buyback / retirement
↑ Increase — issuance / equity compensation
Latest
* most recent reported · FMP /income-statement · weightedAverageShsOut

Annual shares outstanding by year

FY 2025Latest
Diluted Shares: 31.1M
31.1M
+87.21%
FY 2024
Diluted Shares: 16.6M
16.6M
-18.79%
FY 2023
Diluted Shares: 20.5M
20.5M
+0.00%
FY 2022
Diluted Shares: 20.5M
20.5M
+0.00%
FY 2021
Diluted Shares: 20.5M
20.5M
FMP /income-statement · weightedAverageShsOut · weightedAverageShsOutDilUnit: Billions (B)

Healthcare sector shares outstanding comparison

Shares Outstanding for similar companies or competitors in the Healthcare sector.

#SymbolCompanyShares (Basic)vs BBOT
#1
Merck & Co., Inc.MRK
Merck & Co., Inc.
2.502B+>999%
#2
Johnson & JohnsonJNJ
Johnson & Johnson
2.429B+>999%
#3
AbbVie Inc.ABBV
AbbVie Inc.
1.780B+>999%
#4
AstraZeneca PLCAZN
AstraZeneca PLC
1.550B+>999%
#5
UnitedHealth Group IncorporatedUNH
UnitedHealth Group Incorporated
910.0M+>999%
#6
Eli Lilly and CompanyLLY
Eli Lilly and Company
898.0M+>999%
#7
BridgeBio Oncology Therapeutics Inc.BBOT
BridgeBio Oncology Therapeutics Inc.YOU
31.1M

/company-screener · per-peer /income-statement · cache 86400s

Understanding Shares Outstanding

What Are Shares Outstanding? (Basic)

BridgeBio Oncology Therapeutics Inc. (BBOT) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of December 31, 2025, BridgeBio Oncology Therapeutics Inc. reports 31.1M basic shares outstanding (weighted average).

Basic vs. Diluted Shares Outstanding

BridgeBio Oncology Therapeutics Inc.'s basic shares outstanding (31.1M) represents currently issued shares. Diluted shares outstanding (31.1M) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +0.00%.

Shares Outstanding vs. Float (Free Float)

BridgeBio Oncology Therapeutics Inc.'s float is — (— of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.

Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.

FMP /income-statement · /shares-float · SEC EDGAR · USD

About shares outstanding & methodology

BridgeBio Oncology Therapeutics Inc. (BBOT) shares outstanding history from 2021 to 2025. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.

BridgeBio Oncology Therapeutics Inc. shares outstanding for the fiscal year ending December 31, 2025 were 31.1M, a 87.21% increase year-over-year. BridgeBio Oncology Therapeutics Inc. FY 2025 shares outstanding were 31.1M, a +87.21% increase from FY 2024.

BridgeBio Oncology Therapeutics Inc. is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of — — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.

Figures tie to SEC 10-K/10-Q income statement disclosures and FMP /income-statement · /shares-float where noted.

Frequently asked questions

BBOT shares outstanding · 4 questions

As of December 31, 2025, BridgeBio Oncology Therapeutics Inc. (BBOT) has approximately 31.1M basic shares outstanding and 31.1M diluted shares outstanding. This represents a +87.21% year-over-year increase from FY 2024 (16.6M). The increase may reflect equity compensation issuances or secondary offerings.

BBOT shares outstandinghow many shares does BBOT haveBBOT basic shares 2025BBOT diluted shares

Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · BridgeBio Oncology Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-09